28463
document
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder . Atypical antipsychotics have been shown to improve disruptive and repetitive behaviors in pervasive developmental disorders ( PDDs ) , but they require assessment of potential side effects . This is the first placebo-controlled trial of olanzapine in the treatment of children and adolescents with PDD . Eleven patients with a diagnosis of either autism , Asperger 's syndrome , or PDD not otherwise specified ( PDD-NOS ) and aged 6-14 years were randomized into an 8-week double-blind , placebo-controlled , parallel treatment study with olanzapine . There was a significant linear trend x group interaction on the Clinical Global Impressions- Improvement ( CGI-I ) and 50 % on olanzapine versus 20 % on placebo were responders . Olanzapine was associated with significant weight gain ( 7.5 +/- 4.8 lbs vs. 1.5 +/- 1.5 lbs on placebo ) . Olanzapine may be a promising treatment for improving global functioning of PDDs , but the risk of significant weight gain remains a concern . Additional studies are needed to determine the efficacy and safety of olanzapine in the treatment of children with PDD .
28464
Intervention_Control
placebo-controlled
28465
Intervention_Pharmacological
olanzapine
28466
Intervention_Control
placebo-controlled
28467
Intervention_Pharmacological
olanzapine
28468
Intervention_Control
placebo-controlled
28469
Intervention_Pharmacological
olanzapine
28470
Outcome_Mental
disruptive and repetitive behaviors
28471
Outcome_Adverse-effects
side effects
28472
Outcome_Mental
Clinical Global Impressions- Improvement ( CGI-I )
28473
Outcome_Physical
significant weight gain
28474
Outcome_Mental
global functioning of PDDs
28475
Outcome_Physical
weight gain
28476
Participant_Age
childhood/adolescent
28477
Participant_Condition
pervasive developmental disorder
28478
Participant_Sample-size
Eleven
28479
Participant_Condition
autism
28480
Participant_Condition
Asperger 's syndrome
28481
Participant_Condition
PDD
28482
Participant_Condition
PDD-NOS
28483
Participant_Age
6-14 years